Ardelyx, Inc. Reports New Financial Obligation
Ticker: ARDX · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1437402
| Field | Detail |
|---|---|
| Company | Ardelyx, Inc. (ARDX) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $50.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, financing
Related Tickers: ARDX
TL;DR
Ardelyx just took on a new financial obligation, details TBD.
AI Summary
On March 1, 2024, Ardelyx, Inc. filed an 8-K to report the creation of a direct financial obligation. The filing does not specify the exact nature or amount of the obligation, but it indicates a new financial commitment for the company.
Why It Matters
This filing signals a new financial commitment or debt for Ardelyx, Inc., which could impact its financial health and future investment decisions.
Risk Assessment
Risk Level: medium — The creation of a new financial obligation can introduce financial risk if not managed properly, but the lack of specific details prevents a higher risk assessment.
Key Players & Entities
- ARDELYX, INC. (company) — Registrant
- March 1, 2024 (date) — Date of earliest event reported
FAQ
What is the specific nature of the direct financial obligation reported by Ardelyx, Inc.?
The filing does not specify the exact nature of the direct financial obligation.
What is the dollar amount of the new financial obligation?
The filing does not disclose the dollar amount of the financial obligation.
When was this financial obligation created or reported?
The earliest event reported related to this obligation was on March 1, 2024.
Does this filing relate to any off-balance sheet arrangements?
Yes, the filing indicates an obligation under an off-balance sheet arrangement as well as a direct financial obligation.
What is Ardelyx, Inc.'s primary business?
Ardelyx, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-03-05 16:21:08
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat
- $50.0 million — rdelyx, Inc. (the we, us, our) received $50.0 million of funding (Term C Loan) pursuant to th
Filing Documents
- ardx-20240301.htm (8-K) — 26KB
- ardx-20240301_g1.jpg (GRAPHIC) — 3KB
- 0001628280-24-008908.txt ( ) — 159KB
- ardx-20240301.xsd (EX-101.SCH) — 2KB
- ardx-20240301_lab.xml (EX-101.LAB) — 24KB
- ardx-20240301_pre.xml (EX-101.PRE) — 13KB
- ardx-20240301_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 5, 2024 ARDELYX, INC. By: /s/ Justin Renz Justin Renz Chief Financial and Operations Officer